The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes.
D HicksG RafieeE C SchwalbeC I HowellJ C LindseyR M HillA J SmithP AdidharmaC SteelS RichardsonL PeaseM DanilenkoS CrosierA JoshiStephen B WhartonThomas S JacquesB PizerA MichalskiD WilliamsonS BaileySteven C CliffordPublished in: Neuropathology and applied neurobiology (2020)
Investigations of large, retrospective cohorts have enabled the comprehensive and robust characterization of molecular heterogeneity within iMB. Novel subtypes are clinically significant and subgroup-dependent survival models highlight opportunities for biomarker-directed therapies.